Ovid Therapeutics Inc. announced the appointment of Barbara G. Duncan to the company’s board of directors, where she will serve as chairperson of the Audit Committee. Ms. Duncan previously served as the chief financial officer and treasurer at Intercept Pharmaceuticals Inc. Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical Inc., including chief financial officer and ultimately serving as chief executive officer prior to DOV’s sale to Euthymics Bioscience Inc. in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read Inc. and Lehman Brothers Inc. She currently serves on the board of Aevi Genomic Medicine Inc., Jounce Therapeutics Inc., Adaptimmune Therapeutics plc, Innoviva Inc. and ObsEva SA.